Enzymes for Research, Diagnostic and Industrial Use
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
| Catalog | Product Name | EC No. | CAS No. | Source | Price |
|---|---|---|---|---|---|
| CZY-027 | Human Prekallikrein | Human | Inquiry |
Prekallikrein (PK), also known as Fletcher factor, is a plasma protein produced primarily by the liver. This glycoprotein zymogen is converted into active kallikrein, an essential enzyme in several physiological processes, by factor XII (Hageman factor), giving it a central role in the kallikrein-kinin system (KKS). Studies have elaborated on the contact activation system of blood coagulation and inflammation, and prekallikrein is recognized as central to these activities.
Numerous roles are attributed to prekallikrein. Its primary function is to serve as a precursor for plasma kallikrein (PKa), which expedites the formation of bradykinin, mediating inflammation and many other processes. Furthermore, it plays pivotal roles in blood coagulation, fibrinolysis, and thrombosis. Its activation affects blood pressure by releasing kinin, promoting vascular permeability, smooth muscle contraction, and platelet function. Its multifunctionality further extends to innate immunity and endothelial function.
The regulation of prekallikrein activity represents a tightly orchestrated process involving various factors and mechanisms. Activation of prekallikrein occurs through proteolytic cleavage mediated by factors such as factor XIIa, thrombin, and kallikrein itself. Additionally, cofactors like high molecular weight kininogen and zinc ions play pivotal roles in modulating prekallikrein activation and subsequent kallikrein-mediated functions. Beyond activation, the inhibition of prekallikrein activity serves as a critical mechanism to prevent unchecked coagulation and inflammatory responses. Factors such as C1 inhibitor and α2-antiplasmin act as key regulators of prekallikrein and kallikrein, exerting control over their proteolytic activities to maintain a delicate balance between procoagulant and anticoagulant pathways.
Prekallikrein remains inactive until engaged by factor XII, converting it to active kallikrein (PKa). PKa then interacts with high-molecular-weight kininogen (HK), cleaving it and giving rise to bradykinin. Bradykinin, a potent vasodilator, influences vascular function and blood pressure regulation. The PK-HK complex forms the Hageman factor-dependent pathway, a cornerstone of the contact system of intrinsic blood coagulation.
In clinical settings, prekallikrein holds multiple implications. Its alteration affects hemostasis, thrombosis, inflammation, and blood pressure. Plasma prekallikrein level measurement aids diagnosing patients with PK deficiency, a condition increasing the risk of deep vein thrombosis. Another potential application lies in pharmaceuticals, where its inhibition may help reduce pathological thrombosis and inflammation without impinging normal hemostasis. Due to its impact on innate immunity and endothelium, it also lends promising directions in treating cardiovascular diseases.
Gaining knowledge about prekallikrein will shed light on complex hemostatic network regulation, inflammatory responses, and other physiological processes. Clinically, patients with prekallikrein deficiency exhibit bleeding issues, rendering it critical in hemostatic control. Research demonstrates that elevated levels are linked with severe diseases, such as sepsis, acute lung injury, and stroke. Hence, its sullying can serve as a potential marker for pathological states, warranting further investigation to streamline therapeutic strategies.
As a central clog of the kallikrein-kinin system, prekallikrein's pivotal roles in blood coagulation, inflammation, and innate immunity are indisputable. Its modulation embodies promising therapeutic potential—wielding the power to influence hemostasis and hypercoagulable states. Further research to unmask its nuanced regulatory mechanisms will offer superior therapeutic strategies for numerous conditions, from thrombosis to sepsis. The multifaceted nature of prekallikrein development and activation forms an intriguing area of study, boasting of enormous implications in physiology and clinical scenarios.
